Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 27.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 472,028 shares of the company's stock after acquiring an additional 100,586 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.83% of Harmony Biosciences worth $16,242,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in HRMY. Pacer Advisors Inc. boosted its holdings in Harmony Biosciences by 18.2% in the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company's stock valued at $78,452,000 after purchasing an additional 351,582 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company's stock worth $26,416,000 after buying an additional 140,690 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Harmony Biosciences by 13.8% in the fourth quarter. Bank of New York Mellon Corp now owns 265,639 shares of the company's stock valued at $9,141,000 after acquiring an additional 32,272 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company's stock valued at $9,217,000 after acquiring an additional 93,622 shares during the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Harmony Biosciences by 28.4% during the 4th quarter. Principal Financial Group Inc. now owns 208,663 shares of the company's stock worth $7,180,000 after acquiring an additional 46,194 shares in the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. HC Wainwright reduced their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a "buy" rating on the stock in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft assumed coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a report on Tuesday, February 25th. Finally, Mizuho raised their price target on shares of Harmony Biosciences from $42.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 18th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Buy" and an average target price of $53.33.

Harmony Biosciences Stock Performance

Shares of Harmony Biosciences stock traded down $1.04 during trading on Monday, hitting $34.24. 593,085 shares of the stock were exchanged, compared to its average volume of 527,250. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 12 month low of $28.14 and a 12 month high of $41.61. The stock's fifty day moving average is $36.42 and its 200 day moving average is $35.58. The stock has a market cap of $1.96 billion, a PE ratio of 16.23, a P/E/G ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.74 by $0.11. The firm had revenue of $201.30 million during the quarter, compared to analysts' expectations of $201.25 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. Harmony Biosciences's quarterly revenue was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.45 EPS. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sandip Kapadia sold 1,775 shares of the business's stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $38.05, for a total transaction of $67,538.75. The disclosure for this sale can be found here. Insiders have sold a total of 72,452 shares of company stock worth $2,831,679 in the last three months. 30.80% of the stock is owned by company insiders.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.